Emcure Pharmaceuticals Ltd and Novo Nordisk India today announced a strategic partnership to launch Poviztra® (semaglutide injection 2.4 mg) in India. This collaboration marks a significant step towards expanding access to advanced weight management solutions across the country.
Under this partnership, Emcure Pharma will serve as the exclusive distributor responsible for the commercialisation and marketing of Poviztra®, ensuring the product reaches a wider patient population, particularly in regions beyond Novo Nordisk India’s existing network.
Poviztra® is the second brand of Wegovy®, Novo Nordisk’s globally recognized semaglutide injection 2.4 mg, which was launched in India in June 2025. Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management and for reducing the risk of major adverse cardiovascular events in individuals with overweight or obesity.
Clinical studies have shown that 1 in 3 participants using Wegovy® experienced over 20% weight loss, making semaglutide one of the most effective pharmacological treatments for obesity management available today.
With Poviztra®, Novo Nordisk India aims to broaden access to its innovative obesity therapy and meet the growing demand for safe and effective weight-loss medications in India.
Semaglutide 2.4 mg (Wegovy®/Poviztra®) is backed by strong clinical evidence from multiple global obesity trials conducted under the STEP and SELECT programmes. The molecule has been on the market for nearly a decade, with 38 million patient-years of exposure, supported by extensive real-world evidence and clinical safety data.
